Heron Therapeutics Inc. (HRTX)

[gfp927z]

Phase 3 results for APF-530
(complete response rates) -


1) Acute Onset CINV with Moderately Emetogenic Chemo -

APF-530 -- 76.9 %
Aloxi ------- 75.0 %


2) Acute Onset CINV with Highly Emetogenic Chemo -

APF-530 -- 59.0 %
Aloxi ------- 57.7 %


3) Delayed Onset CINV with Moderately Emetogenic Chemo -

APF-530 -- 81.3 %
Aloxi ------- 80.7 %


4) Delayed Onset CINV with Highly Emetogenic Chemo -

APF-530 -- 68.3 %
Aloxi ------- 66.4 %